MorphoSys News

MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib

MorphoSys AG (NASDAQ:MOR) is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment.Myelofibrosis is a type of blood cancer characterized by the

Benzinga34minutes ago

MorphoSys AG Announces Major Shareholder Update

TipRanksApr 29 10:57 ET

Impacted by reports of drug safety issues, Morphosys (MOR.US) says the Novartis Pharmaceuticals (NVS.US) acquisition will continue as planned

The Zhitong Finance App learned that on Monday, the stock price of German biotech company Morphosys (MOR.US) fell due to a news report about its drugs or safety risks, but Morphosys said that Novartis Pharmaceuticals (NVS.US) is still expected to complete its acquisition in the first half of this year. Prior to Morphosys' statement, the professional website StatNews quoted two people familiar with the matter as reporting that the company is developing an experimental drug pelabresib to treat myelofibrosis (a rare type of blood cancer affecting bone marrow)

Zhitong FinanceApr 29 08:21 ET

New Safety Risk for MorphoSys Drug Could Complicate Novartis Deal - STAT

A new safety risk related to Morphosys's (NASDAQ:MOR) pelabresib, an experimental treatment for myelofibrosis, could complicate the company's planned $3B sale to Novartis (NYSE:NVS).

Seeking AlphaApr 28 20:52 ET

MorphoSys AG Announces Shift in Major Holdings

TipRanksApr 26 10:57 ET

MorphoSys AG Sees Shift in Major Shareholders

TipRanksApr 25 12:00 ET

MorphoSys AG Unveils Cancer Drug Trial Progress

TipRanksApr 24 11:57 ET

MorphoSys AG Shares Shift in Major Holdings

TipRanksApr 24 10:57 ET

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

EQS-News: MorphoSys AG / Key word(s): ConferenceMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting 24.04.2024 / 16:40 CET/

MorphoSysApr 24 00:00 ET

Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends

Tuesday, Incyte Corporation (NASDAQ:INCY) agreed to acquire Escient Pharmaceuticals for $750 million.Escient's pipeline includes EP262, a small molecule antagonist of Mas-related G protein-coupled rec

BenzingaApr 23 15:03 ET

Morgan Stanley Adjusts Stake in MorphoSys AG

TipRanksApr 22 11:58 ET

MorphoSys AG Reports Change in Major Holdings

TipRanksApr 19 10:57 ET

MorphoSys AG Reports Shift in Voting Rights

TipRanksApr 18 11:27 ET

MorphoSys Shareholding Shift With Barclays' Increased Stake

TipRanksApr 16 10:57 ET

MorphoSys AG Form SC TO-T/Amended Shows Novartis BidCo AG Bought 2,023,370 Shares Of Common Stock Or About A 5.36% Stake; Highest Price Paid Was €67.95 Per Share

On 11 April 2024, Novartis BidCo, Basel, Switzerland, ("Bidder") has published the offer document regarding its takeover offer (cash offer) to the shareholders of MorphoSys AG, Planegg, Germany ("Morp

BenzingaApr 15 15:55 ET

MorphoSys AG Reports Major Norwegian Stake

TipRanksApr 12 11:57 ET

Trending: Novartis Begins Tender Offer for MorphoSys Shares

1535 ET -- MorphoSys is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Novartis began its tender offer for MorphoSys shares, wit

WSJApr 11 15:36 ET

MorphoSys and Novartis Maintain Expectation Closing of Takeover Offer Be in 1H >MOR

MorphoSys and Novartis Maintain Expectation Closing of Takeover Offer Be in 1H >MOR

Dow JonesApr 11 08:41 ET

MorphoSys: Acceptance Period Has Commenced and Will End on May 13 >MOR

MorphoSys: Acceptance Period Has Commenced and Will End on May 13 >MOR

Dow JonesApr 11 08:39 ET

MorphoSys: Novartis Offers EUR 68.00 Per Shr in Cash, Representing Total Equity Value of EUR 2.7 B >MOR

MorphoSys: Novartis Offers EUR 68.00 Per Shr in Cash, Representing Total Equity Value of EUR 2.7 B >MOR

Dow JonesApr 11 08:39 ET